Intravenous (IV) Solution Market Overview
The emergence of the intravenous (IV) solutions market is attributed to the increasing geriatric population coupled with prevalence of malnutrition in the elderly population. This market is estimated to expand at a CAGR of 7.69% during the forecast period to reach a value of USD 11,511.2 million by 2022. The commonness of cancer is anticipated to quickly increment by around 70% in the following scarcely any decades. Stomach malignant growth is one of the main 5 diseases influencing the populace. These patients are ‘nil by mouth’ and need to depend on Total Parenteral Nutrition (TPN) for survival. Besides, a few patients enduring with cutting edge disease create anorexia, which decreases their survival time. These patients react inadequately to chemotherapy and experience the ill effects of raised harmfulness. This condition is reduced by fringe or all out parenteral sustenance.
An enormous partner of the populace over 60 years or more is available over the globe, which is inclined to creating gastrointestinal, cardiovascular, and neurological illnesses, wounds, and malignancies. Then again, headway in surgeries and medications has expanded the future. The various surgeries require medicinal consideration, thusly bringing about longer hospitalization. IV nourishment shapes a necessary piece of any treatment to satisfy dietary prerequisites and help in quicker recuperation in patients.
In July 2016, a state government in India suggested to all the hospitals regarding taking appropriate precautionary measures before the medical use of IV solutions. Programs including Special Nutrition Program, Integrated Child Development Service Program, and CARE Assisted Nutrition Programs, by the government to offset the existent problem of malnutrition in the country. These kinds of programs are estimated to propel growth of the global intravenous (IV) solutions market.
Intravenous (IV) Solution Market Competitive Analysis:
The key players operating in the global Intravenous (IV) solutions market include Fresenius Kabi AG, B. Hospira, Braun Melsungen AG, and Baxter. The players are trying to offer newer products for several health conditions.
Intravenous (IV) Solution Market Segmentation:
The global Intravenous (IV) solutions market is segmented based on type, nutritional content, end users, and region.
In terms of type, the global Intravenous (IV) solutions market is categorized into peripheral parenteral nutrition, and total parenteral nutrition.
Based on the nutritional content, the market is segmented into amino acid solution, carbohydrates, vitamins & minerals, parenteral lipid emulsion, and other.
Based on the end user, the market is segmented into hospital & clinics, ambulatory, and home care. Of these, the hospital and clinics segment stood largest share with a value of USD 3,111 million in 2016.
Intravenous (IV) Solution Market Regional Analysis:
Based on the region, the market is segmented into Europe, the Americas, Asia Pacific, the Rest of the World (RoW). Of these, the North America is estimated hold strong position in the global Intravenous (IV) solutions market owing to presence of the U.S. and Canada. Among these, the U.S. is estimated to hold the most shares in the market by the end of forecast period. Moreover, the industry giants are trying to offer newer products in the region as the investment in the healthcare is higher. Despite the demand of the solutions is high in the region; however, the U.S. experiences a shortage of saline solutions.
Browse Full Report with TOC at: https://www.marketresearchfuture.com/reports/intravenous-solution-market-1235
However, Asia Pacific is anticipated to emerge as the fastest growing region during the forecast period owing to presence of India as a major consumer in the region. Increasing private funds and government initiatives in the region and especially in the country are likely to help the region in this growth.